Real-world outcomes of neoadjuvant treatment for HER2 positive early-stage breast cancer.

e18791Background: Patients with HER2 positive early-stage breast cancer (ESBC) with residual disease (RD) following neoadjuvant therapy derive benefit from treatment escalation. However, treatment ...